{"organizations": [], "uuid": "a6805d8e1c109b8b9f3dc0cfe4c1910b33db053c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-verona-pharma-says-positive-top-li/brief-verona-pharma-says-positive-top-line-data-from-phase-2b-trial-of-rpl554-idUSFWN1R7027", "country": "US", "domain_rank": 408, "title": "BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2B Trial Of RPl554", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.57, "site_type": "news", "published": "2018-03-26T14:30:00.000+03:00", "replies_count": 0, "uuid": "a6805d8e1c109b8b9f3dc0cfe4c1910b33db053c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-verona-pharma-says-positive-top-li/brief-verona-pharma-says-positive-top-line-data-from-phase-2b-trial-of-rpl554-idUSFWN1R7027", "ord_in_thread": 0, "title": "BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2B Trial Of RPl554", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-verona pharma says positive top-line data from phase", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "verona pharma", "sentiment": "negative"}, {"name": "verona pharma plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Verona Pharma Plc:\n* VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2B CLINICAL TRIAL OF RPL554 FOR MAINTENANCE TREATMENT OF COPD\n* PRIMARY ENDPOINT MET; RPL554 PRODUCED CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN LUNG FUNCTION AT ALL DOSES\n* VERONA PHARMA - CLINICALLY RELEVANT SECONDARY ENDPOINTS WERE ALSO MET, INCLUDING STATISTICALLY SIGNIFICANT, PROGRESSIVE IMPROVEMENTS IN COPD SYMPTOMS\n* RPL554 WAS WELL TOLERATED AT ALL DOSE LEVELS IN THIS FOUR WEEK 400 PATIENT STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T14:30:00.000+03:00", "crawled": "2018-03-27T11:55:01.002+03:00", "highlightTitle": ""}